Latamed AI Corp. authorizes 5M shares of Series C Voting Preferred Stock (20 votes/share)

LataMed AI Corp.

Board designated Series C Voting Preferred Stock: 5,000,000 shares authorized, non-convertible, non-redeemable.
Each Series C share carries 20 votes, voting with common stock as a single class on all matters.
Liquidation preference senior to common stock; dividends at board's discretion, subject to senior securities.
Protective provisions require majority vote of Series C holders for actions that create senior stock, amend terms, or dissolve company.
Certificate of Designation filed with Nevada Secretary of State on May 6, 2026.

item 5.03 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001477932-26-002848
form_type: 8-K
ticker: CCTC
cik: 0001477960
company_name: LataMed AI Corp.
filed_at: 2026-05-08T23:59:59+00:00
discovered_at: 2026-05-14T18:02:32.341041+00:00
generated_at: 2026-05-14T21:03:29.183875+00:00
sec_items: ["5.03", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.4
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001477932-26-002848
json_url: https://secwatch.observer/filing/0001477932-26-002848.json
markdown_url: https://secwatch.observer/filing/0001477932-26-002848.md
text_url: https://secwatch.observer/filing/0001477932-26-002848.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1477960/000147793226002848/0001477932-26-002848-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1477960/000147793226002848/cctc_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001477932-26-002848

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.